Rosetta Genomics Ltd, Rehovot, Israel, with US headquarters in Princeton, NJ, has contracted directly with FedMed Inc, Rockville, Md, and Fortified Provider Network Inc (FPN), Scottsdale, Ariz, for Rosetta’s Cancer Origin Test™.
“Together with Medicare reimbursement, we estimate that the total number of potential covered lives for which the Cancer Origin Test could be adjudicated as ‘in-network’ exceeds 100 million,” says Kenneth A. Berlin, president and CEO. “We continue to pursue additional agreements with other PPOs as they provide faster payment while maintaining acceptable levels of reimbursement, and also reduce costs incurred through appealing denials.”
- FedMed is a Preferred Provider Organization (PPO) with more than 550,000 physicians, 4,000 hospitals, and 60,000 ancillary care providers nationwide. It is estimated that more than 40 million Americans have access to its National Provider Network.
- FPN is a national direct-contracted preferred provider network that represents aoutt four million covered individuals. Its select provider network is used by self-funded employer groups, insurance carriers, and regional and local provider networks that process end-user patient claims.
A PPO is a managed care organization of medical doctors, hospitals and other health care providers that has covenanted with an insurer or a third-party administrator to provide health care at reduced rates to the insurer’s or administrator’s clients.
The Rosetta Cancer Origin Test can accurately identify the primary tumor type in primary and metastatic cancer including cancer of unknown or uncertain primary (CUP).
[Source: Rosetta Genomics]
